Carvedilol prevents myocardial fibrosis in hamsters

Shuji Nanjo; Junichi Yamazaki; Kohki Yoshikawa; Toshiharu Ishii; Yuko Togane

doi:10.1536/ihj.47.607

Carvedilol prevents myocardial fibrosis in hamsters

Shuji Nanjo, Junichi Yamazaki, Kohki Yoshikawa, Toshiharu Ishii, Yuko Togane

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

The objective of the present study was to determine if carvedilol protects against myocardial degeneration and fibrotic change, and reduces mortality in TO2 hamsters. Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day. There were 15 TO2 hamsters in the carvedilol group (group C) and 10 in the untreated group (group N). The control group consisted of 11 Fb hamsters (group F). The mortality rate was determined from the number of surviving hamsters after 29 weeks. Myocardial fibrosis was evaluated by MW and histopathological examination. EF and LVDd were determined by echocardiography at 8 and 29 weeks, while the MRI score was calculated at 29 weeks. Mortality, histopathological fibrosis, and MRI score were all lower in group C than in group N. Carvedilol had a protective effect against myocardial fibrosis and decreased the mortality rate in TO2 hamsters.

Original language	English
Pages (from-to)	607-616
Number of pages	10
Journal	International Heart Journal
Volume	47
Issue number	4
DOIs	https://doi.org/10.1536/ihj.47.607
State	Published - 7 Sep 2006
Externally published	Yes

Keywords

β-blocker therapy
Bio 53.58 hamster
MRI

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1536/ihj.47.607

Cite this

@article{a900c7fe320244f19eadf23678cf814d,

title = "Carvedilol prevents myocardial fibrosis in hamsters",

abstract = "The objective of the present study was to determine if carvedilol protects against myocardial degeneration and fibrotic change, and reduces mortality in TO2 hamsters. Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day. There were 15 TO2 hamsters in the carvedilol group (group C) and 10 in the untreated group (group N). The control group consisted of 11 Fb hamsters (group F). The mortality rate was determined from the number of surviving hamsters after 29 weeks. Myocardial fibrosis was evaluated by MW and histopathological examination. EF and LVDd were determined by echocardiography at 8 and 29 weeks, while the MRI score was calculated at 29 weeks. Mortality, histopathological fibrosis, and MRI score were all lower in group C than in group N. Carvedilol had a protective effect against myocardial fibrosis and decreased the mortality rate in TO2 hamsters.",

keywords = "β-blocker therapy, Bio 53.58 hamster, MRI",

author = "Shuji Nanjo and Junichi Yamazaki and Kohki Yoshikawa and Toshiharu Ishii and Yuko Togane",

year = "2006",

month = sep,

day = "7",

doi = "10.1536/ihj.47.607",

language = "英語",

volume = "47",

pages = "607--616",

journal = "International Heart Journal",

issn = "1349-2365",

publisher = "International Heart Journal Association",

number = "4",

}

TY - JOUR

T1 - Carvedilol prevents myocardial fibrosis in hamsters

AU - Nanjo, Shuji

AU - Yamazaki, Junichi

AU - Yoshikawa, Kohki

AU - Ishii, Toshiharu

AU - Togane, Yuko

PY - 2006/9/7

Y1 - 2006/9/7

N2 - The objective of the present study was to determine if carvedilol protects against myocardial degeneration and fibrotic change, and reduces mortality in TO2 hamsters. Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day. There were 15 TO2 hamsters in the carvedilol group (group C) and 10 in the untreated group (group N). The control group consisted of 11 Fb hamsters (group F). The mortality rate was determined from the number of surviving hamsters after 29 weeks. Myocardial fibrosis was evaluated by MW and histopathological examination. EF and LVDd were determined by echocardiography at 8 and 29 weeks, while the MRI score was calculated at 29 weeks. Mortality, histopathological fibrosis, and MRI score were all lower in group C than in group N. Carvedilol had a protective effect against myocardial fibrosis and decreased the mortality rate in TO2 hamsters.

AB - The objective of the present study was to determine if carvedilol protects against myocardial degeneration and fibrotic change, and reduces mortality in TO2 hamsters. Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day. There were 15 TO2 hamsters in the carvedilol group (group C) and 10 in the untreated group (group N). The control group consisted of 11 Fb hamsters (group F). The mortality rate was determined from the number of surviving hamsters after 29 weeks. Myocardial fibrosis was evaluated by MW and histopathological examination. EF and LVDd were determined by echocardiography at 8 and 29 weeks, while the MRI score was calculated at 29 weeks. Mortality, histopathological fibrosis, and MRI score were all lower in group C than in group N. Carvedilol had a protective effect against myocardial fibrosis and decreased the mortality rate in TO2 hamsters.

KW - β-blocker therapy

KW - Bio 53.58 hamster

KW - MRI

UR - https://www.scopus.com/pages/publications/33749061531

U2 - 10.1536/ihj.47.607

DO - 10.1536/ihj.47.607

M3 - 記事

C2 - 16960415

AN - SCOPUS:33749061531

SN - 1349-2365

VL - 47

SP - 607

EP - 616

JO - International Heart Journal

JF - International Heart Journal

IS - 4

ER -

Carvedilol prevents myocardial fibrosis in hamsters

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this